Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14889MR)

This product GTTS-WQ14889MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14889MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10745MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ13617MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ13014MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ4724MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ9251MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ6252MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ8082MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ15410MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TSR-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW